Dr Reddy's Labs rises 4% on receiving EIR for Hyderabad plant
The formulation manufacturing plant-3 Bachupally was issued a form 483 by the USFDA with 11 observations.
By ETMarkets.com | Updated:
NEW DELHi: Shares of Dr Reddy's Labs advanced nearly 4 per cent in Tuesday's trade after the company said its recently USFDA audited plant in Hyderabad has received establishment inspectaion report (EIR) from the US drug regulator
The formulation manufacturing plant-3 Bachupally was issued a form 483 by the USFDA with 11 observations.
The scrip closed Tuesday's session 2.83 per cent up at Rs 2255.60.
On the BSE, 49,000 shares were traded on the counter so far as against the average daily volumes of 33,000 shares in the past two weeks
The stock had hit a 52-week low of Rs 1,901.65 on 11 August 2017. The company made the announcement after Monday's trading hours.
Brokerage Motilal Oswal Securities is neutral on the stock with a target of Rs 2,575.
The formulation manufacturing plant-3 Bachupally was issued a form 483 by the USFDA with 11 observations.
The scrip closed Tuesday's session 2.83 per cent up at Rs 2255.60.
On the BSE, 49,000 shares were traded on the counter so far as against the average daily volumes of 33,000 shares in the past two weeks
The stock had hit a 52-week low of Rs 1,901.65 on 11 August 2017. The company made the announcement after Monday's trading hours.
Brokerage Motilal Oswal Securities is neutral on the stock with a target of Rs 2,575.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Seven Bangladeshis illegally staying in Hyderabad apprehended, deportation process begins2026-06-13T14:03:32Z- Lufthansa Frankfurt-Hyderabad flight receives bomb threat email2026-06-13T07:23:52Z
- How 4 cm of rain brought Hyderabad’s IT corridor to a crawl; commuter spends 4 hours covering a few km2026-06-10T03:38:12Z
ADVERTISEMENT
